13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002043476
Total reported value
$213.0M
$213.0M
19 檔
44.7%
The Q1 2025 SEC filing reveals that B Group, Inc. held a total portfolio value of $213.0M, covering 19 public equity positions.
During Q1 2025, B Group, Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including ADMA, INSM, ZLAB) accounted for 44.7% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ADMA | Adma Biologics Inc | Stock-Healthcare | 39.39% | -8.61% | +1.31% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 17.16% | — | -25.00% | |
| 3 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 12.38% | -2.26% | — | |
| 4 | AKRO | Akero Therapeutics Inc | Stock-Other | 8.41% | — | -6.73% | |
| 5 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 4.28% | -0.97% | +51.21% | |
| 6 | CLLS | Cellectis - Adr | Stock-Other | 3.46% | -3.09% | +5.68% | |
| 7 | AURA | Aura Biosciences Inc | Stock-Other | 2.37% | -0.41% | — | |
| 8 | SGHT | Sight Sciences Inc | Stock-Other | 1.71% | -0.99% | +32.45% | |
| 9 | ASMB | Assembly Biosciences Inc | Stock-Other | 1.64% | -1.34% | +294.86% | |
| 10 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.50% | -0.21% | +30.03% | |
| 11 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.47% | +0.02% | +525.33% | |
| 12 | BNTX | Biontech Se-adr | Stock-Other | 1.17% | — | +328.57% | |
| 13 | ✓ | Ultragenyx Pharmaceutical In | Stock-Other | 1.17% | — | +27.46% | |
| 14 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.97% | -0.82% | +40.00% | |
| 15 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.96% | -0.47% | EXIT | |
| 16 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.62% | -2.72% | — | |
| 17 | ETNBGBP | 89bio Inc | Stock-Other | 0.60% | — | — | |
| 18 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.51% | +0.62% | +191.07% | |
| 19 | ✓ | Corvus Pharmaceuticals Inc | Stock-Other | 0.25% | — | -10.00% |
According to official SEC Form 13F filings, B Group, Inc. reported a total U.S. public equity portfolio value of $213.0M across 19 disclosed positions in Q1 2025.
During Q1 2025, B Group, Inc.'s top holdings by market value included ADMA (39.4%)、INSM (17.2%)、ZLAB (12.4%). The largest single position, ADMA, represented 39.4% of total portfolio value.
In Q1 2025, B Group, Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.